Wave Life Sciences

WVE

3.4803.42% ( +0.115 )

Closed: Nov 9, 16:00:00 (EDT)

Q3 FY2026 EarningsQ3 FY26 results featured a significant top-line beat with revenue of $13.2M vs. $4.4M expected, primarily driven by collaboration milestones. GAAP EPS of -$0.30 outperformed the -$0.33 consensus due to controlled net losses and a higher share count. With $431.0M in cash and a runway extended into Q3 2028, the company is well-positioned for its upcoming registrational trial of WVE-006 and Phase 2a readouts for WVE-007.

Financial report interval: 2026.06.30 - 2026.09.30

Overview: Wave Life Sciences(WVE) the Revenue is 13.16 M (+72.95%), Beat estimate;the EBIT is -66.05 M (-17.2%), Beat estimate;the EPS is -0.3 (+6.25%), Beat estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.01B72.95%

0.00B42.28%

+0.01B115.23%

EBITExceed expectations

-0.07B17.20%

-0.07B24.57%

+0.00B7.37%

EPSExceed expectations

-0.36.25%

-0.33394.35%

+0.033910.60%

Upcoming earnings report - Annual FY2026

Available dateFeb 26, 2027

Estimate Revenue$62.97 M

Estimate EBIT-$241.43 M

Estimate EPS-$1.1105

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly